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Summary 
Despite efforts to develop vaccines that protect against malaria by inducing CD8 + T  cells that 
kill infected hepatocytes, no subunit vaccine has been shown to circumvent the genetic restric- 
tion inherent in this approach, and little is known about the interaction of subunit vaccine- 
induced immune effectors and infected hepatocytes. We now report that immunization with 
plasmid DNA encoding the Plasmodium yoelii  circumsporozoite protein protected one of five 
strains  of mice against malaria (H-2  a, 75%);  a PyHEP17 DNA vaccine protected three of the 
five strains  (H-2  a, 71%; H-2  k, 54%; H-2  a, 26%); and the combination protected 82% of H-2  a, 
90% of H-2  k, and 88% of H-2  a mice. Protection was absolutely dependent on CD8 + T  cells, 
IFN-~/, or nitric oxide. These data introduce a new target of protective preerythrocytic im- 
mune responses, PyHEP17 and its P. falciparum homologue, and provide a realistic  perspective 
on the opportunities and challenges inherent in developing malaria vaccines that target the in- 
fected hepatocyte. 
I 
mmunization with radiation-attenuated Plasmodium spp. 
.sporozoites  induces  sterile  protective  immunity  against 
malaria in  rodents,  primates,  and humans  (for review see 
reference  l). Protection is dependent on CD8 § T  cells in 
some rodent models (2,  3), and CD8 + T  cells can protect 
in the absence of other immune responses (4-7). Immunity 
is  presumably mediated  via  CD8 +  T  cell  recognition  of 
parasite-derived peptides that are presented on the surface 
of infected hepatocytes in  association with  class  I  MHC 
molecules; hepatocytes are the only cell in the parasite's fife 
cycle known to express class I MHC molecules. That CD8 + 
CTLs can recognize an epitope from the Plasmodium yoelii 
circumsporozoite protein (PyCSP)  1 expressed on P.  yoelii- 
infected hepatocytes (8), and that MHC-restricted immune- 
mediated elimination of  infected hepatocytes that are express- 
ing parasite Ags  can protect against  sporozoite-transmitted 
malaria  (9)  have  been  demonstrated.  Accordingly,  there 
have been  efforts  to  develop subunit vaccines that  induce 
protective CD8 + T  cells. To be effective in a heterogeneous 
population, however, such vaccines must contain multiple 
protective CD8 + T  cell epitopes restricted by diverse class I 
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MHC  alleles  (10,  11).  Only a few of such epitopes have 
been  identified in  mice,  and  all  have  been  on  the  H-2  a 
background (4-7), and subunit vaccine-induced CD8 + T 
cell-dependent protection has  only been demonstrated in 
H-2  a  mice.  Furthermore,  it  is  not  known  whether  the 
CD8 + T  cells lyse the infected hepatocytes directly, as clas- 
sical CTLs (for review see  reference  12),  or indirectly via 
mediators such as cytokines that induce the infected hepa- 
tocyte to inactivate or kill the parasite.  It has  been estab- 
fished, however, that IFN-~/is active against infected hepa- 
tocytes (2, 6, 13-17). Reports indicate that IFN-~ produced 
by CD8 + T  cells induces infected hepatocytes to produce 
L-arginine-derived nitrogen oxides that are toxic to the in- 
tracellular parasite (18-22). 
The irradiated sporozoite vaccine is impractical for large- 
scale  human use, and progress in developing subunit vac- 
cines that induce protection comparable to that induced by 
the irradiated sporozoite vaccine has been slow (for review 
see reference  1). We recently reported (23) that immuniza- 
tion  of BALB/c  mice  with  plasmid  DNA  encoding the 
PyCSP  induces  more  potent  in  vitro  cytolytic  activity 
against  a nonamer epitope on the PyCSP than does immu- 
nization with irradiated sporozoites and induces CD8 + T 
cell-dependent protection.  These data  raise  crucial issues 
concerning the  efficacy of the  PyCSP DNA  vaccine  on 
non-BALB/c backgrounds  as  a  consideration  for human 
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DNA-induced protective immunity. 
We now report that (a) protective immunity induced by 
the  PyCSP  DNA  vaccine  is  genetically  restricted;  (b)  a 
DNA  vaccine  based  on  the  gene  encoding  the  recently 
identified 17-kD liver-stage protein designated P. yoelii hepa- 
tocyte erythrocyte protein (PyHEP17)  (24) induces protec- 
tion with a  different pattern of genetic restriction;  (c) im- 
munization with the PyCSP-PyHEP17 DNA combination 
solidly protects mice of three genetic backgrounds, circum- 
venting the genetic restriction of protection to the individ- 
ual components;  and  (d)  the protective immunity directed 
against the parasite developing within hepatocytes is com- 
pletely eliminated by in vivo depletion of CD8 §  T  cells, 
treatment  with  anti-IFN-%  or  inhibition  of nitric  oxide 
production. 
Materials and Methods 
Construction ofPlasmid DNA.  The nkCMVintpolyli vector has 
been described previously (23); expression of the encoded gene is 
driven by a CMV immediate/early  gene promoter. The PyHEP17 
DNA vaccine was constructed by cloning a 342-bp cDNA frag- 
ment representing the complete exon  1 plus 57%  of exon 2  of 
PyHEP17  (Doolan,  D.L.,  R.C.  Hedstrom,  W.D.  Rogers,  Y. 
Charoenvit, M. Rogers, P. de la Vega, and S.L. Hoffman, manu- 
script submitted for publication) into the PstI site of nkCMVint- 
polyli. This  construct does not include (Charoenvit, Y., unpub- 
fished data) the region of the PyHEP17 protein recognized by the 
mAb, NYLS3, used to identify PyHEP17 (24). The PyCSP DNA 
vaccine has been previously described (23). 
In Vitro Expression.  Expression of the PyHEP17 plasmid DNA 
was assessed in vitro by two methods. First, COS cells (American 
Type Culture Collection [ATCC], RockviUe, MD) were trans- 
fected with 10 ng of plasmid DNA by calcium phosphate copre- 
cipitation (25). mRNA was extracted from the transfected COS cells 
with the Micro FastTrack mRNA isolation kit (Invitrogen, San 
Diego, CA). Reverse transcription (RT)-PCR was then performed 
using each of oligo(dT), random hexamer- and specific oligonu- 
cleotide-primed and DNAase (Boehringer Mannheim Corp., In- 
dianapolis, IN)-treated first-strand cDNA as the template (Super- 
script Preamplification System for First-Strand cDNA synthesis; 
GIBCO BRL, Gaithersburg, MD). RT-PCR revealed that frag- 
ments of a size corresponding to the cDNA representing exon 1 
and 57% of exon 2 of PyHEP17 were amplified and were smaller 
than fragments amplified from genomic DNA template. The am- 
plified fragments hybridized to PyHEP17-specific  probes (data not 
presented).  Second, sera from mice immunized with the PyHEP17 
DNA vaccine recognized the transfected COS cells,  as demon- 
strated by the indirect fluorescent Ab test (data not presented). 
Mice and Parasites.  Female 6- to 8-wk-old BALB/cByJ, A/J, 
B10.BR,  B10.Q,  and  C57BL/6  mice  (the Jackson Laboratory, 
Bar Harbor, ME) and outbred CD-1 mice (Charles RAver Labo- 
ratories, Wilmington, MA) were used in all studies. P. yoelii (17X 
NL nonlethal strain, clone 1.1) was maintained by alternating pas- 
sages of the parasites in Anopheles stephensi mosquitoes and CD-1 
mice. Sporozoites were obtained 14 d  after an infectious blood 
meal by hand-dissection of P. yoelii 17X NL-infected mosquito 
glands in  M199  medium  containing  5%  normal  mouse  serum 
(Rockland, Inc., GilbertsviUe, PA) as previously described (3) and 
diluted to a final concentration of 100 infectious sporozoites per 
0.2-ml vol. Erythrocytic-stage parasites were obtained from hep- 
arinized blood of a BALB/CByJ mouse 10 d after a previous in- 
fection, washed in PBS, and diluted to a final concentration of 200 
infected erythrocytes per 0.2-ml vol, calculated on the basis ofpara- 
sitemia at the time of harvest. 
Immunizations and Challenges.  Female 6- to 8-wk-old mice were 
immunized three times at 3-wk intervals intramuscularly in each 
tibialis anterior muscle with 50 p~g of PyHEP17 DNA in 50 btl of 
saline, 20 ~g of PyCSP DNA, a mixture of 50 ~g of PyHEP17 
DNA and 20  p~g of PyCSP DNA,  or unmodified nkCMVint- 
polyli plasmid.  2  wk  after the  third immunization,  mice  were 
challenged by tail-vein injection with 100 infectious sporozoites 
("~50  IDs0; reference 26)  or 200  infected erythrocytes. Giemsa- 
stained blood smears were examined on days 5-14, up to 50 oil- 
immersion fields being scanned for parasites.  Protection was  de- 
fined as the complete absence of blood-stage parasitemia. 
Antibodies.  Purified  rat  Ig  was  purchased  from  Rockland, 
Inc. The anti-CD4 + mAb GK1.5 (rat IgG2a) was obtained from 
ATCC  (TIB207)  and has been previously described (27).  The 
anti-CD4 +  mAb YTA3.1.2  (rat IgG2b) was provided by Dr.  H. 
Waldmann and  has  been  previously described  (28).  The  anti- 
CD8 +  mAb  2.43  (mouse  IgG2a)  was  obtained  from  ATCC 
(TIB210) and has been previously described (29). The anti-IFN-~./ 
mAb XMG-6 (rat IgG1) was provided by Dr.  F. Finkelman and 
has been previously described (30). All Igs were purified from as- 
cites  (Harlan Bioproducts for Science,  Indianapolis, IN)  by 50% 
ammonium  sulphate  precipitation, and  final Ab  concentrations 
were determined by optical density. 
Depletions.  Immunized mice were treated as follows. Unde- 
pleted: On days -7,  -6,  -5,  -4,  -3,  -2,  and 0  (relative to 
challenge with 100 P. yoelii sporozoites on day 0), mice received 
a single intraperitoneal dose of 1.3 mg of purified rat Ig. CD4 + 
in 0.2 ml PBS T  cell depletion: On days -7,  -6,  -5,  -4,  -3, 
-2, 0, and +2, mice received a single intraperitoneal dose of 1.0 
mg and 0.3 mg, respectively, of the anti-CD4 § mAbs GK1.5 and 
YTA3.1.2.  CD8 + T  cell depletion: On days -5,  -4,  -3,  -2, 
and 0, mice received a single intraperitoneal dose of 0.5  mg of 
the anti-CD8 + mAb 2.43. Treatment with anti-IFN-~/: On days 
-4,  -3,  -2,  -1  and +2, mice received a single intraperitoneal 
dose of 1.0 mg of the anti-IFN-~/mAb XMG-6. Treatment with 
aminoguanidine: Twice daily, commencing 24 h before sporo- 
zoite challenge and continuing for 72 h after challenge, mice were 
administered 50  mg aminoguanidine  (Si~aaa Chemical Co.,  St. 
Louis, MO) per kg body wt in 0.5 ml PBS via gastric lavage. 
FACScan  |  (Becton Dickinson & Co.).  The extent of Ab deple- 
tion was determined by performing single-color FACS  |  Approx- 
imately 106  cells of the population to be analyzed were stained 
with either anti-CD8 + FITC or anti-CD4  + FITC (Pharmingen, 
San Diego,  CA) for  1 h  at 4~  Unstained and FITC controls 
were  included for each sample.  Stained cells were washed three 
times, resuspended in paraformaldehyde (0.5% vol/vol), and stored 
at 4~  until analyzed. FACScan  |  (FAX 4000 Royal; Becton Dick- 
inson  Immunocytometry Systems,  San Jose,  CA)  was  used  for 
analysis of the samples. 
Serology.  Mice were bled for serum ,--,2 wk after each  im- 
munization.  Sera  were  assayed  by  indirect fluorescent Ab  test 
against air-dried P. yoelii sporozoites, liver-stage parasites, or blood- 
stage parasites as previously described (31). 
Results 
PyCSP DNA  Vaccine Protects against  Malaria  on  a  Single 
Genetic Background.  Both MHC  and non-MHC genes con- 
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sponses  to  P. falciparum,  P.  vivax,  P.  yoelii, and  P.  berghei 
CD8 +  and  CD4 +  T  cell  epitopes  and B  cell  epitopes  are 
also known to be genetically restricted  (for review see ref- 
erence 33).  Previously, we reported that BALB/c mice are 
protected  against  sporozoite  challenge  by  inununization 
with PyCSP DNA  (23). We wanted  to assess  the capacity 
of PyCSP DNA to confer protection in mice of other ge- 
netic backgrounds. Five inbred mouse strains were selected 
for  the  immunization  studies  on  the  basis  of differences 
in both  genetic  background  and  H-2  haplotypes:  BALB/ 
cByJ  (H-2KalaDaLa);  A/J  (H-2KkIkDaLa); B10.BR/SgSnJ 
(H-2KklkD~Lk);  B10.Q/SgJ  (H-2KqlqDqLq);  and  C57BL/ 
6J,  (H-2KblbDt'Lb).  Only in BALB/c mice was protection 
>20% (Table  1). 
The CSP is a principal candidate Ag for preerythrocytic 
vaccine development (34). The data presented here predict 
that anti-CSP  CD8 + T  cell responses alone will,  however, 
be inadequate  to protect an outbred human population.  A 
vaccine designed to protect humans by inducing CD8 + T 
cells  that  recognize  8-10  amino  acid peptides  complexed 
with  class  I  HLA molecules  on  infected  hepatocytes  will 
therefore  have  to  include  epitopes  from multiple  parasite 
proteins. 
PyHEPI 7 DNA  Vaccine Protects against Malaria on Multi- 
ple Genetic Backgrounds.  Localization of the recently identi- 
fied liver- and blood-stage Ag PyHEP17 in P. yoelii-infected 
hepatocytes (24) suggested that,  like the CSP, this Ag may 
be a target of protective T  cell responses directed at the in- 
Table  1.  Genetic Restriction of the Protective Immunity Induced by 
fected  hepatocyte,  To  investigate  this,  in vivo protection 
studies were carried out with a PyHEP17 DNA vaccine in 
the  same  five  inbred  mouse  strains  differing  in  genetic 
background  and  H-2  haplotype  studied  with  the  PyCSP 
DNA  vaccine.  Immunization  with  PyHEP17  DNA  par- 
tially protected three of the five strains >20% against chal- 
lenge with 100 infectious sporozoites (Table  1). A  2 to 6-d 
delay  in  the  onset  of parasitemia  in  some  nonprotected 
mice  (data  not presented)  was  consistent  with  partial  im- 
munity,  which  eliminated  up  to  90%  of infected  hepato- 
cytes. 
Outbred CD-1 mice were subsequendy studied.  Consis- 
tent with the range of protection in the inbred strains.  40% 
(8 of 20) of the CD-1 mice immunized with three doses of 
100 ~g PyHEP17 DNA were protected against sporozoite 
challenge. 
Bi-gene DNA Immunization Circumvents the Genetic Restric- 
tion of Proteaion of the Univalent DNA  Vaccines.  Data indicated 
that  protective  immunity  after  immunization  with  either 
PyHEP17 or PyCSP plasmid DNA is genetically restricted: 
A/J  mice  are  high  responders  to  PyHEP17  and  low  re- 
sponders to PyCSP, and BALB/c  mice are high responders 
to PyCSP and low responders to PyHEP17; B10.BR mice 
are moderate responders  to PyHEP17 and low responders 
to  PyCSP;  B10.Q  and  C57BL/6  mice are  low or nonre- 
sponders  to  both  Ags.  We  therefore  determined  whether 
immunization of  mice with a PyHEPI 7-PyCSP DNA com- 
bination  could  enhance  the  protection  and/or  protect  on 
more  than  one  genetic  background.  Both  high responder 
Immunization with PyHEP17DNA, PyCSPDNA, or the Combination 
DNA vaccine  Strain  H-2 haplotype 
No. protected 
out of no.  Percent 
IFAT titers (l/x)  challenged  protection 
PyCSP  BALB/c  d  10,240  18 of 24  75 
A/J  a  10,240  6 of 32  19 
B10.BR.  k  320-640  1 of 12  8 
BI0.Q  q  40-160  0 of 7  0 
C57 BL/6  b  10,240  0 of 17  0 
PyHEP17  BALB/c  d  0-160  9 of 34  26 
A/J  a  0--40  25 of 35  71 
B10.BR,  k  0-80  20 of 37  54 
B10.Q  q  0-80  2 of 12  17 
C57 BL/6  b  1617)-640  0 of 19  0 
PyHEPI 7 + PyCSP  BALB/c  d  15 of 17  88 
A/J  a  22 of 27  82 
B10.BR  k  27 of 30  90 
BI0.Q  q  1 of 7  14 
C57 BL/6  b  0 of 7  0 
Data represent accumulated results of up to four separate experiments with a total of 585 mice. All naive mice (149 mice) and all control mice im- 
munized with the nkCMVintpolyli plasmid (119 mice) became infected. 
PyHEPI7 antibody titers were assessed by IFAT against P. yoelii blood-stage parasites. PyCSP Ab titers were assessed by IFAT against P. yoelii  sporo- 
zoites. Data represent the range of titers obtained from individual mouse sera. 
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90% of the moderate responder B10.BIL (H-2  ~) mice (Ta- 
ble  1) were protected with the combination. Although no 
C57BL/6  (H-2  b)  and  only  14%  of B10.Q  (H-2q)  mice 
were protected,  in most mice a delay in the onset of para- 
sitemia of up to 4 d was noted with the combination, com- 
pared  with  either  of the  vaccines  alone  (data  not  pre- 
sented). 
Thus, bivalent DNA immunization protected mice of di- 
verse genetic backgrounds and H-2 haplotypes, circumvent- 
ing the genetic restriction of protection found after immuni- 
zation with the PyCSP or PyHEP17 DNA vaccines delivered 
alone.  The  results  are  not related  to  the  dosage of DNA, 
since the quantity of DNA used in the combination exper- 
iments reported here (100 Ixg PyHEP17 plus 40 p~g PyCSP) 
is Lower than that used in previous studies with either the 
PyHEP17 DNA (200 Ixg) or PyCSP DNA (200 p,g), where 
no effect of the increased DNA dose was observed (data not 
presented). 
DNA-induced  Protection Is  Dependent upon CD8 + T  Cells. 
The protective immune responses induced by the PyHEP17 
DNA vaccine must be directed against the infected hepato- 
cyte. First,  immunity cannot be directed against sporozoites 
in  the  circulation,  since  PyHEP17  is  not  expressed  in 
sporozoites and is  first  expressed  within  6  h  of sporozoite 
invasion  of hepatocytes  (24).  Second, immunity is not di- 
rected against the  erythrocytic stage of the parasite life cy- 
cle, which commences when the parasites are released from 
infected hepatocytes, since there was no protection against 
challenge  with  200  infected  erythrocytes  (data  not  pre- 
sented).  Third,  sera  from  mice  immunized  with  the 
PyHEP17 DNA did not recognize P. t,  oelii liver-stage par- 
asites  and  recognized  P.  yoelii erythrocytic-stage  parasites 
by IFAT only at very low levels  (Table  1),  and  there  was 
no  correlation  between  Ab  titers  and  protection  against 
sporozoite challenge (Table 1). 
To determine whether a specific subset ofT cells was re- 
quired for the DNA-induced protection, we conducted in 
vivo depletion  studies.  In six of the  eight different groups 
of mice, CD4 + T  cell depletion did not lead to any reduc- 
tion  in  protection  (Table  2).  However,  in  B10.BP~  mice 
immunized with PyHEP17 DNA, protection was reduced 
from 75 to 50% by CD4 § T  cell depletion, and in BALB/c 
mice immunized with the PyHEP17-PyCSP DNA combi- 
nation, protection was reduced from 80 to 40% after CD4* 
depletion  (Table  2).  These  data  may reflect  the variability 
of the  protection  after  DNA  immunization  in  general  or 
may be indicative of a role for CD4 § T  cells in DNA vac- 
cine-induced protection in these mice. Since the reduction 
only occurred in two  of the  eight groups,  and  the  differ- 
ences  were  not  statistically  significant  (Fisher's  exact  P 
value: B10.BR nfice immunized with the PyHEP17 vaccine, 
0.377;  BALB/c  mice  immunized  with  the  combination 
vaccine,  0.1698),  we  favor  the  former  explanation.  In 
marked  contrast,  however,  CD8 §  T  cell  depletion  coin- 
pleted  eliminated  protection  in  all  groups  of immunized 
mice  (Table  2).  Therefore,  protective  immunity after im- 
munization with  PyHEP17 DNA and with the  PyHEP17- 
PyCSP DNA combination is entirely dependent  on CD8 § 
T  cells.  Consistent with this finding,  MHC-restricted  Ag- 
specific  CD8 +  CTLs  are  induced  in  mice  by  PyHEPI7 
DNA immunization (Doolan, L.D., unpublished data). 
DNA-induced  Protection Is Dependent upon IFN-'y and Nitric 
Oxide.  We reasoned that DNA vaccine-induced anfi-PyCSP 
and PyHEP17 CD8 + T  cells are eliminating infected hepa- 
tocytes, as demonstrated with irradiated sporozoite-induced 
CD8 §  T  cells  (8,  9).  In vitro and in vivo data indicate that 
IFN-~/produced by malaria-specific CD8 + T  cells stimulate 
Plasmodium-infected  hepatocytes  to  eliminate  the  parasite 
by  producing  nitric  oxide  (19,  20,  22).  To  determine 
whether the PyHEPI 7, PyCSP, or PyHEP17-PyCSP com- 
bination DNA vaccines induce the same pathway, B10.BR 
nfice were immunized and treated before sporozoite chal- 
lenge with either anti-lFN-~/mAb  or aminognanidine,  an 
Table 2.  Elimination  qf Protective Immunity by In Vivo Depletion qf CD8 + T Cells 
Percent protection 
(no. protected out of no. challenged) 
DNA vaccine  Strain  Undepleted  CD4 + depleted  CD8 § depleted 
P),HEP  t 7  A/J  43  (3 of 7)  78  (7 of 9)  (~  (0 of 9) 
BALB/c  22  (2 of 9)  22  (2 of 9)  C)  (0 of 9) 
B10.BR  75  (9 of 12)  50  (5 of 10)  I)  (0 of 10) 
PyCSP  A/J  11  (1 of 9)  11  (1 ofg)  t)  (tl of 9) 
BALB/c  56  (5 of 9)  56  (5 of 9)  I)  (0 of 9) 
PyHEPI 7 + PyCSP  A/J  80  (8 of 10)  913  (9 of 10)  (I  ((1 of 10) 
BALB/c  80  (8 of 10)  411  (4 of 10)  I)  (ll of 10) 
B10.BR  90  (9 of 10)  90  (9 of 10)  (~  (I) of 10) 
One mouse per group was killed on the day of challenge to assess depletion with FACScan. The efticiencies of CD4 + and CD8  + T cell depletion 
were estimated as 99 and 96%, respectively. 
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Percent protection (no. protected out of no. challenged) 
Vaccine  Strain  Undepleted  IFN-3~ depleted  iNOS depleted 
P),HEP17  B10.BP,.  75 (9 of 12)  0 (0 of 10)  0 (0 of 10) 
PyHEP17 + PyCSP  B10.BR  90 (9 oft0)  0 (0 of 10)  0 (0 of 10) 
inhibitor of the  inducible  isoform of nitric  oxide synthase 
(iNOS)  (35).  The results show that there is an absolute re- 
quirement  for both  IFN-~/ and  nitric  oxide  in  the  DNA 
vaccine-induced protective immunity (Table 3). 
Discussion 
The data presented here identify PyHEP17 (24) as a new 
target of protective immune responses directed against the 
infected  hepatocyte  and  systematically define  the  process 
whereby effector CD8 + T  cells  induced by immunization 
with a single gene or bi-gene DNA malaria vaccine recog- 
nize the infected hepatocyte and eliminate the capacity of 
that cell to sustain a viable plasmodial infection. The data also 
emphasize the absolute requirement for such a vaccine to 
induce protective T  cell responses against multiple parasite 
proteins if it is to be effective in a heterogeneous population. 
Genetic restriction of protective CD8 + T  cell responses 
is expected, since the T  cell receptor can only recognize its 
target peptide when that 8-10-amino acid peptide is com- 
plexed with a class I MHC molecule, with specific amino 
acid restrictions on the formation of that complex (for re- 
view see reference 36). Nonetheless, we were surprised that 
immunization  with  the  PyCSP  DNA  vaccine  only  pro- 
tected one of five strains of inbred mice (see Table 1). The 
PyCSP gene encodes a protein of 391  amino acids and we 
expected,  apparently  inappropriately,  that  the  PyCSP 
would contain protective CD8 § T  cell epitopes recognized 
by class I  MHC  molecules from multiple  strains  of mice. 
Inbred  mice  are  different  from  outbred  humans;  how- 
ever, this finding certainly suggests that it may be inappro- 
priate to construct a human malaria vaccine designed to in- 
duce  protective  CD8 +  T  cell  responses  directed  against 
only the CSP. 
The studies presented here demonstrate that it is possible 
to circumvent genetic restriction ofCD8 + T  cell-mediated 
protective immunity against individual Plasmodium spp. pro- 
teins expressed in infected hepatocytes by immunizing with 
more than one protein. This may appear obvious, but there 
are only a few examples of this phenomenon after immuni- 
zation with subunit vaccines (37-39).  Furthermore, immu- 
nization  with  two  peptides  representing  defined  CD8 + 
CTL epitopes on the CSP often leads to less cytolytic activ- 
ity against either one than does immunization with the in- 
dividual peptide  (Franke,  E.D.,  personal communication). 
Additional work is required to determine whether additive 
protection  will  be  obtained  with  all  DNA  vaccines,  or 
whether it is restricted to the responses to certain Ags. 
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The  irradiated  sporozoite  vaccine  has  been  the  model 
and gold standard for preerythrocytic stage malaria vaccine 
development. In BALB/c mice, immunization with irradi- 
ated sporozoites, but not with DNA, can confer 100% sterile 
protective  immunity  against  massive sporozoite  challenge 
(Sedegah,  M.,  unpublished  data).  In contrast,  Weiss et al. 
(32)  reported  that  only 31%  of B10.BR.  mice were  pro- 
tected against challenege with 5,000 P. yoelii sporozoites af- 
ter immunization  with  irradiated  sporozoites;  this protec- 
tion was not dependent on CD8 + T  cells.  Here, we report 
that the PyCSIX-PyHEP17 combination protected 90% of 
B10.BR mice against challenge with  100  P. yoelii sporozo- 
ites after DNA immunization with the  PyCSP-PyHEP17 
combination (see  Table 1);  this protection was completely 
dependent  on  CD8 +  T  cells  (see  Table 2).  Therefore,  in 
B 10.BR mice, the bi-gene DNA vaccine may provide bet- 
ter  CD8 +  T  cell-dependent  protection  against  P.  yoelii 
than  does  the  whole  organism vaccine.  It is  unlikely  that 
the  bi-gene  DNA  vaccine  contains  more  CD8 +  T  cell 
epitopes recognized by H-2  k B10.BR  mice than does the 
irradiated sporozoite vaccine, or that "cryptic" epitopes are 
exposed by DNA immunization.  It is more probable that, 
as demonstrated for PyCSP in H-2  d BALB/c mice (23), the 
DNA vaccine is  inducing  a  much more potent  CD8 +  T 
cell  response  against  epitopes  presented  by  both  systems 
than  is  the  irradiated  sporozoite  vaccine.  Certainly,  such 
protection may be better than that afforded by repeated ex- 
posure to malaria in the field, where sterile immunity does 
not occur (40)  and malaria-specific CD8 +  CTL responses 
are low (41-43). 
Despite  a  large  literature  referring to  protective  CD8 + 
CTLs  (for  review  see  reference  1),  the  phenomenon  of 
classical  cytolytic activity with direct contact between the 
effector T  cell and the infected target cell and subsequent 
lysis of the target cell by CD8 + CTLs (for review see refer- 
ence  12)  has never been established in  malaria. Although 
CSP-  and  sporozoite  surface  protein  2-specific  CD8 §  T 
cell  clones  with  cytolytic  activity  can  adoptively transfer 
protection  (4-7),  it  is  not  known  whether  the  activity 
against the infected hepatocytes is cytolytic. In fact, it has 
been shown  that the protective activity of one such anti- 
PyCSP  CTL  clone  is  abrogated  by in  vivo  treatment  of 
mice with anti-IFN-~/ (6),  and that in two strains of mice, 
the protective immunity induced by immunization with ir- 
radiated P. berghei sporozoites is reversed by in vivo treat- 
ment of the  mice with anti-lFN-~/  (2,  22).  The data pre- 
sented here suggest that the activity of protective CD8 + T 
cells  against  Plasmodium-infected  hepatocytes  is  not  via  a classical cytolytic mechanism. The protection is completely 
reversed by in vivo depletion  of CD8 +  T  cells,  by treat- 
ment with anti-IFN-% or by inhibiting the inducible iso- 
form of nitric  oxide  synthase.  We interpret  these  findings 
to  indicate  that  the  CD8 +  T  cell activated by interacting 
with the MHC-peptide  complex on the surface of the in- 
fected hepatocyte secretes IFN-% The IFN-~/then induces 
the infected hepatocyte to produce nitric oxide that renders 
the  parasite  noninfectious.  This  may  in  part  explain  the 
multitude  of reports  in  both  rodent  and  human  systems 
showing  that  the  induction  of CTLs  against  Plasmodium 
spp. proteins does not correlate with protection of the host 
(44-48). 
This study lays the foundation for multigene DNA vac- 
cines (for reviews see references 49 and 50) designed to at- 
tack infected human hepatocytes and identifies  the  newly 
discovered P. falciparum  homologne of PyHEP17  (Doolan, 
D.L., et al.  manuscript submitted for publication)  as a can- 
didate  component of any such multivalent vaccine.  How- 
ever, it must be placed in perspective. Some strains of mice 
were not protected,  and all challenge work was done with 
a parasite clone. If there is any hope of producing long-last- 
ing protection in heterogeneous human populations,  addi- 
tional  genes  will  have  to  be  included  to  overcome  the 
MHC restriction ofT cell responses and the antigenic poly- 
morphism of the parasite  at T  cell epitopes.  The exquisite 
dependency of this protection on each of the individual ef- 
fectors---CD8  +  T  cells,  IFN-%  and  nitric  oxide  under- 
scores the long-term complexity of developing an effective 
hepatocyte-targeted malaria vaccine.  It seems obvious that 
an effective vaccine that functions by killing infected hepa- 
tocytes will have to be as complex and elegant as its parasite 
opponent. 
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